Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on etoposide-containing medicinal products - Direct communication with healthcare professionals on etoposide-containing medicinal products
Direct communication with healthcare professionals on etoposide-containing medicinal products
Etoposide: Risk of infusion-related hypersensitivity reactions when administered with an in-line filter.
Summary
The following recommendations apply only to etoposide and not to etoposide phosphate:
- An increased risk of infusion-related hypersensitivity reactions has been observed with the use of in-line filters during administration of etoposide-containing medicinal products.
- It is currently unknown whether the risk increase occurs with all types of in-line filters or only with in-line filters made of certain materials.
- In-line filters should not be used.
Published on: 04 March 2024
Oggi si celebra il #WorldAutismAwarenessDay.
🔵 L'Agenzia Italiana del Farmaco sostiene la Giornata...
Vai al post →
Jelena Ivanovic, dirigente medico dell’Ufficio Procedure Europee di #HTA di #AIFA, è stata eletta Co...
Vai al post →
Biosimilari: webinar AIFA su terzo Position Paper
La Commissione Scientifica ed Economica (CSE) di ...
Vai al post →
🎙️ Il Presidente #AIFA intervistato da @presadirettarai sulle false terapie a base di cellule stami...
Vai al post →
💛 28 marzo 2026 – Giornata Mondiale dell’Endometriosi 💛
#AIFA si illumina di giallo per accendere...
Vai al post →
🤝🌍 A Roma i lavori dell’EDQM Borderline Products Network Meeting
💬 Il meeting, ospitato da #AIFA...
Vai al post →
